Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-001310-15
    Sponsor's Protocol Code Number:6058-PR-PRI-200
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-09-05
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2013-001310-15
    A.3Full title of the trial
    Biological standardization of Artemisia vulgaris allergen extract to determine the biological activity in histamine equivalent units (HEP).
    Estandarización biológica del extracto alergénico de Artemisia vulgaris para determinar la actividad biológica en unidades equivalentes de Histamina (HEP).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    To determine the minimum amount of Artemisia vulgaris allergen extract producing a positive skin reaction.
    Determinar la cantidad mínima de extracto alergénico de Artemisia vulgaris que produce una reacción cutánea positiva.
    A.4.1Sponsor's protocol code number6058-PR-PRI-200
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLABORATORIOS LETI, S.L.U
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportLABORATORIOS LETI, S.L.U
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationLABORATORIOS LETI, S.L.U
    B.5.2Functional name of contact pointDepartamento Médico
    B.5.3 Address:
    B.5.3.1Street AddressC/ del Sol, 5
    B.5.3.2Town/ cityTres Cantos, Madrid
    B.5.3.3Post code28760
    B.5.3.4CountrySpain
    B.5.4Telephone number349177117413288
    B.5.5Fax number34918037472
    B.5.6E-maildramos@leti.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Prick Test Beifuss LETI 30 HEP/ml (Artemisia vulgaris)
    D.2.1.1.2Name of the Marketing Authorisation holderLETI pharma GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameExtracto alergénico nativo de Artemisia vulgaris
    D.3.4Pharmaceutical form Solution for skin-prick test
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPCutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNExtracto alergenico nativo de Artemisia vulgaris
    D.3.9.2Current sponsor code200
    D.3.9.3Other descriptive nameARTEMISIA VULGARIS POLLEN EXTRACT
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNExtracto alergénico nativo de Artemisia vulgaris
    D.3.9.2Current sponsor code200
    D.3.9.3Other descriptive nameARTEMISIA VULGARIS POLLEN EXTRACT
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNExtracto alergénico nativo de Artemisia vulgaris
    D.3.9.2Current sponsor code200
    D.3.9.3Other descriptive nameARTEMISIA VULGARIS POLLEN EXTRACT
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.1
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNExtrato alergénico nativo de Artemisia vulgaris
    D.3.9.2Current sponsor code200
    D.3.9.3Other descriptive nameARTEMISIA VULGARIS POLLEN EXTRACT
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.01
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeProducto para pruebas cutáneas de diagnóstico in vivo
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDiclorhidrato de histamina 10 mg/ml
    D.3.2Product code Control positivo
    D.3.4Pharmaceutical form Solution for skin-prick test
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPCutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDiclorhidrato de histamina 10 mg/ml
    D.3.9.1CAS number 56-92-8
    D.3.9.3Other descriptive nameHISTAMINE DIHYDROCHLORIDE
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeSe trata de un control positivo para pruebas cutaneas de diagnostico in vivo.
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDiluyente. Solución Salina Fenolada Glicerinada
    D.3.2Product code Control Negativo
    D.3.4Pharmaceutical form Solution for skin-prick test
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPCutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDiluyente. Solución salina Fenolada Glicerinada
    D.3.9.2Current sponsor codeControl Negativo
    D.3.10 Strength
    D.3.10.1Concentration unit Gtt drop(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeSe trata de un control negativo para pruebas cutáneas de diagnóstico in vivo.
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Allergy to Artermisia vulgaris
    Alergia a Artemisia vulgaris
    E.1.1.1Medical condition in easily understood language
    Allergy to Artemisia pollen
    Alergia al polen de Artemisia
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10036019
    E.1.2Term Pollen allergy
    E.1.2System Organ Class 100000004870
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to assess the concentration of Artemisia vulgaris allergen extract that elictis a wheal size equivalent to that of a 10 mg/ml histamine dyhidrochloride solution.
    El objetivo principal consiste en evaluar la concentración de extracto alergénico de Artemisia vulgaris que provoca una pápula de un tamaño equivalente a la producida por una solución de diclorhidrato de histamina a 10 mg/ml.
    E.2.2Secondary objectives of the trial
    The secondary objective is to perform the in vitro characterization of the internal reference preparation from subjects' serum, to determine their in vitro biological potency and to guarantee the cosistency of the biological potency of the product batch by batch
    El objetivo secundario es realizar la caracterización in vitro de dicho PRI a partir del análisis de sueros de los sujetos, para determinar su potencia biológica in vitro y poder garantizar la consistencia de la potencia biológica del producto lote a lote
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Positive clinical history of inhalatory allergy to Artemisia vulgaris with (rhinitis and/or rhinoconjunctivitis and / or asthma)
    -Subject has provided written informed consent, appropriately signed and dated by the subject (or legal representative, if applicable)
    - Subject can be male or female of any race and ethinic group
    - Age ? 18 years and ? 60 years at the study inclusion day
    - A positive prick test with a standardized commercially Artemisia vulgaris allergen extract (Wheal medium diameter ? 3mm or wheal area ? 7 mm2). The skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study
    - A positive test for specific IgE to Artemisia vulgaris (CAP-RAST major or equal to 2). IgE results are valid if performed within one year prior to the inclusion of the subject in the study.
    - Allergy symptoms during the Artemisia vulgaris pollen season.
    - Historia clínica positiva de alergia inhalatoria (rinitis y/o rinoconjuntivitis y/o asma) frente a Artemisia vulgaris .
    - El sujeto (y/o su representante legal, si procede) ha otorgado su consentimiento informado por escrito, y lo ha firmado y fechado debidamente.
    - Sujetos de ambos sexos, de cualquier raza y grupo étnico.
    - Edad ? 18 años y ? 60 años en el día de la inclusión en el ensayo.
    - Un prick test positivo (diámetro medio de la pápula ? 3mm o área de la pápula ? 7 mm2) con un extracto alergénico estandarizado comercial de Artemisia vulgaris. Los resultados de la prueba prick-test serán válidos si se realizaron en el año previo a la inclusión del sujeto en el ensayo.
    - Una prueba positiva de IgE específica de Artemisia vulgaris (CAP-RAST ? 2). Los resultados de la prueba de IgE serán válidos si se realizaron en el año previo a la inclusión del sujeto en el ensayo.
    - Síntomas alérgicos durante la estación polínica de Artemisia vulgaris.
    E.4Principal exclusion criteria
    -Immunotherapy in the past 5 years with an allergen extract Artemisia vulgaris or other allergen extract that may interfere with the allergene to be tested (for example: Helianthus annuus (sunflower) elatior Ambrosia eiator (ambrosia) or peach.
    -Use of drugs that may interfere before and after with the skin reactions (for example: antihistamines). See appendix 1 of the protocol.
    -Treatment with any of the following medications: oral tricyclic or tetracyclic
    antidepressants, beta-blockers, corticosteroids (major 10 mg/daily of prednisone or equivalent).
    - Women who are pregnant or breastfeeding period and women with positive pregnancy test at Visit 2, before skin prick test
    -Dermographism affecting the skin area at the test site at either study visit.
    -Atopic dermatitis affecting the skin area at the test site at either study visit.
    -Urticaria affecting the skin area at the test site at either study visit.
    -Diseases of the immune system relevant clinically, both autoimmune and immunodeficiencies
    -Serious diseases not controlled that may increase the risk for the safety of the subjects involved in this study, including, but not limited to the following: heart failure, uncontrolled or severe respiratory diseases, endocrine diseases, clinically relevant kidney or liver diseases or hematological diseases.
    -Participation in any other clinical trial within 30 days (or 5 times the biological half-life of the research of the study product, whichever is longer) prior to the
    inclusion of the subject in this clinical trial.
    -Patients with diseases or conditions that limit the use of adrenaline (heart disease, severe hypertension, ..)
    -Severe psychiatric, psychological or neurological disorders
    -Abuse of alcohol, drugs or medicines in the previous year.
    -Subjects who have received anti-IgE (Omalizumab)
    -Inmunoterapia en los últimos 5 años con un extracto alergénico de Artemisia vulgaris u otros extractos alergénicos que puedan interferir con el alérgeno a testar por presentar un alto grado de reactividad cruzada (por ejemplo: Helianthus annuus (girasol), Ambrosia eliator (ambrosía) o melocotón.
    -Uso de fármacos que puedan interferir con la respuesta cutánea antes y durante el estudio (por ejemplo: antihistamínicos) dentro de los plazos establecidos en el apéndice 1.
    -Tratamiento con cualquiera de los siguientes medicamentos: antidepresivos tricíclicos, tetracíclicos o IMAOs, betabloqueantes, uso crónico de corticoides orales, o uso de corticoides vía oral o parenteral en pautas repetidas e intermitentes (> 10 mg/día de prednisona o equivalente).
    -Mujeres que estén embarazadas o en periodo de lactancia -Dermografismo que afecte a la zona de la piel en la que se realiza la prueba, en cualquiera de las dos visitas del ensayo.
    -Dermatitis atópica que afecte a la zona de la piel en la que se realiza la prueba, en cualquiera de las dos visitas del ensayo.
    -Urticaria que afecte a la zona de la piel en la que se realiza la prueba, en cualquiera de las dos visitas del ensayo.
    -Enfermedades del sistema inmunitario relevantes clínicamente, tanto autoinmunes como inmunodeficiencias.
    -Enfermedades graves no controladas que puedan aumentar el riesgo para la seguridad de los sujetos que participen en este estudio, incluyendo, pero no limitando, las siguientes: insuficiencia cardiaca, enfermedades respiratorias graves o no controladas, enfermedades endocrinas, enfermedades hepáticas o renales clínicamente relevantes o enfermedades hematológicas.
    -Participación en cualquier otro ensayo clínico en los 30 días (o 5 veces la semivida biológica del producto en investigación del estudio, lo que sea más largo) previos a la inclusión del sujeto en este ensayo clínico.
    -Sujetos con enfermedades o trastornos que limiten el uso de adrenalina (enfermedades coronarias, HTA grave, etc).
    -Trastornos psiquiátricos, psicológicos o neurológicos graves.
    -Abuso de alcohol, drogas o medicamentos en el año anterior.
    -Sujetos que hayan recibido tratamiento anti-IgE (Omalizumab).
    E.5 End points
    E.5.1Primary end point(s)
    The wheal size area (mm2) which is produced on the skin after application of Artemisia vulgaris allergen extract at various concentrations, along with the wheal area induced by the positive control and the negative by Skin prick Test technique.
    El área de la pápula (mm2) que se produce en la piel después de la aplicación del extracto Artemisia vulgaris a distintas concentraciones, junto con el área de las pápulas inducidas por el control positivo y el negativo, mediante la técnica del Skin Prick-Test.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary endpoint will be determined after the last patient last visit (end of study)
    La variable principal se determinara tras la UVUP (fin de estudio)
    E.5.2Secondary end point(s)
    The power of the PRI in vitro will determinate througth the implementation of inmunoassays, and shall be expressed in units of biolofical activity:
    -Specific IgE.
    -Competitive inhibition of specific IgE.
    La potencia del PRI in vitro se determinará mediante la realización de inmunoensayos, y se expresará en unidades de actividad biológica:
    -Determinación de IgE específica.
    -Inhibición competitiva de IgE especifica.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The secondary endpoint will be determined after the last patient last visit (end of study)
    La variable secundaria se determinara tras la UVUP (fin de estudio)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis Yes
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Los parametros de control estarán siempre incluidos en cada uno de los sujetos
    Control parametres are all ways included in each of the subjects
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Control positivo, (Diclorhidrato de Histamina) y Control negativo (solución salina)
    (Positive Control) and (Negative Control)
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LPLV
    UVUP. Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 30
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients No
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The clinical trial is on the diagnosis of Artemisia vulgaris prick test. This section does not apply because of the characteristics of the study (patients do not receive treatment).
    El ensayo clínico es sobre el prick diagnostico de Artemisia vulgaris. Esta sección no aplica debido a las características del estudio(los pacientes no reciben tratamiento).
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-10-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-10-15
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 11:16:49 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA